AbbVie stock: Piper Sandler raises target to USD 349
Published on 11/21/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst targets sharpen AbbVie outlook
- Piper Sandler raised its AbbVie price target and maintained an Overweight rating.
- Barclays also lifted its target during the reporting week.
- Investors are watching pipeline progress and 2027 earnings guidance.
On November 18, Piper Sandler raised its AbbVie price target to USD 349 from USD 303 and maintained an Overweight rating, according to Yahoo Finance. The analyst view puts pipeline execution and future earnings delivery at the center of the valuation discussion.
Barclays had already raised its AbbVie target to USD 335 from USD 325 on November 16 while retaining an Overweight rating. The two revisions gave investors additional sell-side perspectives during the week, although analyst targets remain scenario-based rather than guaranteed outcomes.
Pipeline progress remains in focus
The Piper Sandler assessment highlighted continued Skyrizi growth and early data from combination-drug programs. The report also pointed to 2027 guidance as an important next test for the investment case, with the Apogee transaction and Vraylar pricing among the factors investors are monitoring.
AbbVie stock traded at 260.25 euros on Lang & Schwarz at 10:34 CET on Saturday, November 21, 2026.
AbbVie Inc. at a glance
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- NYSE ticker: ABBV
- Lang & Schwarz quote: 260.25 euros at 10:34 CET on November 21, 2026
- Analyst view: Piper Sandler target of USD 349 and Overweight rating
Broader U.S. market conditions remain relevant for pharmaceutical shares; see Current market reports.
For further company coverage, see More news and analyses on AbbVie stock.
